Indication
Clostridium difficile infection
34 clinical trials
30 products
2 drugs
Clinical trial
A PHASE 3, RANDOMIZED OBSERVER-BLINDED STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDERStatus: Completed, Estimated PCD: 2020-12-22
Product
PlaceboProduct
Clostridium difficileClinical trial
A Randomised, Controlled, Open-label Phase III Clinical Trial in Patients With Primary or Recurrent Clostridioides Difficile (CD) Infection, to Evaluate the Efficacy and Safety of Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin.Status: Completed, Estimated PCD: 2023-11-15
Product
MBK-01Product
DificlirClinical trial
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection: A Phase 2A Open-Label Segment Followed by a Phase 2B Double-Blind Vancomycin-Controlled SegmentStatus: Active (not recruiting), Estimated PCD: 2023-10-03
Product
IbezapolstatProduct
VancomycinProduct
VE303Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile InfectionStatus: Not yet recruiting, Estimated PCD: 2027-06-01
Product
RBX2660Clinical trial
A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (Microbiota Suspension) in Subjects With Recurrent Clostridium Difficile InfectionStatus: Completed, Estimated PCD: 2023-07-21
Clinical trial
CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile InfectionStatus: Completed, Estimated PCD: 2021-06-02
Clinical trial
Clinical Effectiveness of Egg-derived Polyclonal Antibodies (IM-01) for the Treatment of Mild-moderate Clostridium Difficile Infection (CDI)Status: Recruiting, Estimated PCD: 2023-12-30
Product
IM-01Clinical trial
A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDERStatus: Completed, Estimated PCD: 2021-12-21
Clinical trial
A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in AdultsStatus: Completed, Estimated PCD: 2020-07-03
Product
SER-109Clinical trial
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent RecurrenceStatus: Completed, Estimated PCD: 2018-05-01
Product
SER-262Clinical trial
A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS 65 TO 85 YEARS OF AGEStatus: Completed, Estimated PCD: 2019-08-06
Product
placeboClinical trial
A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile InfectionStatus: Completed, Estimated PCD: 2020-04-02
Clinical trial
Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile InfectionStatus: Recruiting, Estimated PCD: 2024-07-30
Product
PlacebosProduct
Fecal Microbiota TransplantClinical trial
Randomized Controlled Clinical Study of Treatment of Clostridioides Difficile Infection Comparing Fecal Microbiota Transplantation With Antibiotic TreatmentStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Product
AntibioticClinical trial
Effect of Proton Pump Inhibitors on the Colonic Microbiome in ChildrenStatus: Terminated, Estimated PCD: 2017-01-01
Product
OmeprazoleClinical trial
Efficacy of Prophylactic Oral Vancomycin in Preventing Recurrent Clostridium Difficile Infection in Hospitalized Patients Requiring AntibioticsStatus: Completed, Estimated PCD: 2022-02-17
Clinical trial
Safety of Fecal Microbiota Transplantation (FMT) for Recurrent or Refractory C. Difficile Infection in Patients With Solid TumorsStatus: Completed, Estimated PCD: 2024-02-16
Clinical trial
A Phase II, Randomized Trial to Evaluate the Optimal Dosing of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products for Recurrent Clostridium Difficile InfectionStatus: Terminated, Estimated PCD: 2021-08-11
Product
Penn Microbiome TherapyClinical trial
A Phase II, Randomized Trial to Evaluate the Safety and Efficacy of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products for Severe or Severe-Complicated/Fulminant Clostridium Difficile InfectionStatus: Terminated, Estimated PCD: 2021-11-21
Product
AntibioticsClinical trial
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection: A Randomized, Double-blind, Placebo-controlled TrialStatus: Recruiting, Estimated PCD: 2026-12-31
Product
Alanyl-glutamineClinical trial
A Multicenter Double Blind Randomized Study Comparing the Efficacy of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplantation (FMT) in the Management of Recurrent Clostridioides Difficile Infection (CDI)Status: Completed, Estimated PCD: 2024-03-12
Clinical trial
Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence. BEFORE StudyStatus: Completed, Estimated PCD: 2021-08-05
Product
BezlotoxumabClinical trial
Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients (Decency-RCT): A Randomized Controlled Pilot TrialStatus: Recruiting, Estimated PCD: 2024-03-01
Product
ProbioticClinical trial
Fecal Microbiota Transplant for Recurrent Clostridium Difficile InfectionStatus: Completed, Estimated PCD: 2018-10-26
Clinical trial
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile InfectionStatus: Completed, Estimated PCD: 2023-07-06
Drug
VarlilumabClinical trial
Screening to Prophylax Against Clostridium Difficile InfectionStatus: Completed, Estimated PCD: 2023-06-28
Clinical trial
A Randomized, Double-Blinded Placebo Controlled Study To Determine the Effectiveness of Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)Status: Terminated, Estimated PCD: 2022-06-11
Clinical trial
Prospective, Open-label Trial to Evaluate Efficacy of 30-day Duration of Fidaxomicin in Patients With Recurrent C. Difficile InfectionStatus: Terminated, Estimated PCD: 2021-08-30
Product
FidaxomicinClinical trial
Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile InfectionStatus: Completed, Estimated PCD: 2023-02-22
Product
Standard CDIClinical trial
Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)Status: Withdrawn, Estimated PCD: 2023-05-01
Clinical trial
Fecal Microbiota Transplantation (FMT) for Moderate to Severe Clostridium Difficile Infection (CDI): A Randomised Study With Concurrent Stool Microbiota Assessment (FMT-CDI-RCT Study)Status: Active (not recruiting), Estimated PCD: 2018-01-01
Clinical trial
Fecal Microbiota Transplantation Versus Standard Medical Therapy for Initial Treatment of Recurrent Clostridium Difficile InfectionStatus: Terminated, Estimated PCD: 2020-01-01
Drug
FMTProduct
Antimicrobials